α6 Nicotinic Acetylcholine Receptors: A Pharmacological Challenge with Untapped Therapeutic Promise
α6-containing nicotinic acetylcholine receptors (α6* nAChRs), particularly the α6β2* and α6β4* subtypes, are promising therapeutic targets for neurological disorders such as nicotine addiction, Parkinson’s disease, and pain. However, progress is signi
Authors
- dongting zhangsun
- Maomao Ren
- Baojian Zhang (ORCID: https://orcid.org/0000-0001-6835-6634)
- Yi-Shan Chen
- Yang Xiong (ORCID: https://orcid.org/0000-0002-9508-1987)
- Linlin Ma (ORCID: https://orcid.org/0000-0002-4716-5158)
- Shuai Dong (ORCID: https://orcid.org/0000-0002-5377-2034)
- Kailin Mao (ORCID: https://orcid.org/0000-0001-9259-6291)
- Lan Su (ORCID: https://orcid.org/0000-0001-8404-0680)
- Bingmiao Gao (ORCID: https://orcid.org/0000-0003-1042-1768)
Institutions
- Griffith University (AU)
- Guangxi University (CN)
- Hainan University (CN)
- Hainan Medical University (CN)
Publication Details
- Published
- 2025-08-20
- DOI
- https://doi.org/10.22541/au.175569060.03472549/v1
- Primary Topic
- Nicotinic Acetylcholine Receptors Study
- Type
- article
- Field-Weighted Citation Impact
- 0.00